Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Children with an aggressive form of the most common childhood brain tumor, medulloblastoma, face a tough prognosis. Effective treatments are limited, and long-term survival is poor. But new hope may be offered by a discovery from St. Jude Children’s Research Hospital involving a pair of drugs used to treat adult cancers.
A St. Jude Children’s Research Hospital-led study identified two adult cancer drugs with potential to improve treatment of a high-risk childhood brain tumor; the drugs are now part of a pediatric clinical trial. (Martine Roussel, PhD)
Martine Roussel, Ph.D., of St. Jude Children’s Research Hospital, has been named to the 2011 class of new Fellows and Foreign Honorary Members of the American Academy of Arts and Sciences.
Researchers at St. Jude have demonstrated for the first time that tiny molecules called microRNAs participate in the initiation and progression of one form of human medulloblastoma, the most common malignant brain cancer in children.
Stopping brain tumor cells from growing sounds like a dream. Turning those cells into normal brain cells sounds like a fantasy. But scientists at St. Jude Children’s Research Hospital are in the process of turning fantasy into reality.
The Ink4c and Ptch1 genes collaborate to suppress the development of the brain tumor medulloblastoma.
Researchers may have found a link between progressive hearing loss and a gene called p19Ink4d (Ink4d), according to the results of a study co-authored by St. Jude investigators, that measured hearing loss in mice lacking that gene.
Researchers may have found a link between progressive hearing loss and a gene called p19Ink4d (Ink4d)